Aortic regurgitation (AR) is a significant complication in patients with left ventricular assist devices (LVADs), leading to poor clinical outcomes due to circulatory inefficiency. Traditional surgical interventions for AR in this population carry high operative risk, and dedicated transcatheter solutions are still under trial and not commercially available. Join a discussion of the JSCAI manuscript presenting the first-in-human case report on the use of the Abbott Navitor self-expanding intra-annular valve for transcatheter aortic valve replacement (TAVR) in patients with LVAD-associated AR, addressing a critical unmet need in patient care.
Accreditation StatementThe Society for Cardiovascular Angiography and Interventions (SCAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit DesignationSCAI designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 0.5 MOC points in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABIM MOC credit.
Successful CompletionWatch the content and complete the evaluation to obtain credit.Activity TimelineRecord Date: 12/4/2025Publish Date: 3/10/2026Expiration Date: 3/10/2029
SCAI accepts the following Content Validation Statements and expects all persons involved in its professional education activities to abide by these statements for clinical care recommendations. All clinical and pharmacological recommendations are based on evidence accepted within the medical profession as adequate jurisdiction for their indications and contradictions in patient care. All research referenced to support or justify patient care recommendations conforms to accepted standards of experimental design, data collection and analysis.
SCAI does not promote recommendations, treatment, or manners of practicing medicine that are not within the definition of accredited continuing education or known to have risks or dangers that outweigh the benefits or known to be ineffective in the treatment of patients.
SCAI actively promotes improvements in health care and NOT proprietary interests of an ineligible company.
SCAI's educational content is free of marketing or sales of products or services. Faculty will not actively promote or sell products or services that serve their professional or financial interests during accredited education. SCAI encourages faculty to identify investigational products or off-label uses of products regulated by the U.S. Food and Drug Administration (FDA), at first mention and where appropriate in the content.